Gene · 710
Papers4,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,981 to 2,000 of 4,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes. | Hum Mutat | 2020 | 31517426 | PubTator, text mining | PubMed |
| Radiotherapy in the setting of hypersensitivity syndromes. | Breast J | 2020 | 31513307 | PubTator, text mining | PubMed |
| Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema. | J Allergy Clin Immunol Pract | 2020 | 31437566 | PubTator, text mining | PubMed |
| A novel C1 inhibitor gene mutation in a family with hereditary angioedema: Use of genetic analysis to facilitate early diagnosis. | Allergol Int | 2020 | 31409531 | PubTator, text mining | PubMed |
| C1 esterase inhibitor in pediatric cardiac surgery with cardiopulmonary bypass plays a vital role in activation of the complement system. | Heart Vessels | 2020 | 31278424 | PubTator, text mining | PubMed |
| Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema. | J Pharm Pract | 2020 | 31234699 | PubTator, text mining | PubMed |
Corrigendum to "Gene mapping strategy for Alu elements rearrangements: Detection of new large deletions in the SERPING1 gene causing hereditary angioedema in Brazilian families" [Gene 685C (2019) 179-185]. | Gene | 2020 | 31153634 | PubTator, text mining | PubMed |
| Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. | Br J Dermatol | 2020 | 31049937 | PubTator, text mining | PubMed |
| Deciphering microbiome and neuroactive immune gene interactions in schizophrenia. | Neurobiol Dis | 2020 | 30471416 | PubTator, text mining | PubMed |
| Degradation of Eight Sulfated Polysaccharides Extracted from Red and Brown Algae and Its Impact on Structure and Pharmacological Activities. | ACS Biomater Sci Eng | 2019 | 33405640 | PubTator, text mining | PubMed |
| The complement system in liver diseases: Evidence-based approach and therapeutic options. | J Transl Autoimmun | 2019 | 32743505 | PubTator, text mining | PubMed |
| Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. | Drugs Context | 2019 | 32158478 | PubTator, text mining | PubMed |
| A case of amniotic fluid embolism successfully treated by multidisciplinary treatment. | JA Clin Rep | 2019 | 32026080 | PubTator, text mining | PubMed |
| Colonic ischemia possibly due to resuscitative endovascular balloon occlusion of the aorta (REBOA) used to manage amniotic fluid embolism: a case report. | JA Clin Rep | 2019 | 32025934 | PubTator, text mining | PubMed |
| Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients. | J Community Hosp Intern Med Perspect | 2019 | 32002148 | PubTator, text mining | PubMed |
| The Influence of ACE Inhibition on C1-Inhibitor: A Biomarker for ACE Inhibitor-Induced Angioedema? | Biomed Hub | 2019 | 31993426 | PubTator, text mining | PubMed |
| Investigation of the underlying hub genes and mechanisms of reperfusion injury in patients undergoing coronary artery bypass graft surgery by integrated bioinformatic analyses. | Ann Transl Med | 2019 | 31930065 | PubTator, text mining | PubMed |
| Two Different Missense C1S Mutations, Associated to Periodontal Ehlers-Danlos Syndrome, Lead to Identical Molecular Outcomes. | Front Immunol | 2019 | 31921203 | PubTator, text mining | PubMed |
| Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma. | Cancer Manag Res | 2019 | 31908537 | PubTator, text mining | PubMed |
| C1 inhibitor in canine intravascular hemolysis (C1INCH): study protocol for a randomized controlled trial. | BMC Vet Res | 2019 | 31888626 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/710/papers?page=100